Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings
September 10, 2024 07:00 ET
|
Entero Therapeutics, Inc.
BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against Metastatic Cancer
September 10, 2024 07:00 ET
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candi-date Revealing Mechanisms Behind Candidate’s Preclinical Efficacy Against
POET Selected by Mentech to Supply Engines for 800G and 1.6T Optical Modules
September 10, 2024 07:00 ET
|
POET Technologies Inc.
TORONTO and SHENZHEN, China, Sept. 10, 2024 (GLOBE NEWSWIRE) -- POET Technologies Inc. (“POET” or the “Company”) (TSX Venture: PTK; NASDAQ: POET), the designer and developer of the POET Optical...
Tonix Pharmaceuticals Announces Appointment of Thomas Englese as Executive Vice President of Commercial Operations
September 10, 2024 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Thomas brings more than 20 years of commercial and operations experience in the biopharmaceutical industry to Tonix Tonix is on track to submit an NDA for TNX-102 SL for fibromyalgia in October of...
ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Surgery
September 10, 2024 07:00 ET
|
ACELYRIN, INC.
Rapid-fire Oral Presentation to Highlight Efficacy, Safety, and Quality of Life Outcomes LOS ANGELES, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical...
Cibus Completes First Field Trials in UK for Pod Shatter Reduction in Winter Oilseed Rape
September 10, 2024 07:00 ET
|
Cibus US LLC
Initial data from Pod Shatter Reduction field trials show promising results The first gene edited trait to complete field trials in oilseed rape in the UK SAN DIEGO, Sept. 10, 2024 (GLOBE...
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
September 10, 2024 07:00 ET
|
Centessa Pharmaceuticals plc
2.5 mg dose restored normative wakefulness with mean sleep latency of 32 minutes as measured by the Maintenance of Wakefulness Test (MWT)Favorable safety and tolerability profile with no observations...
Virtu Financial Announces Direct Connectivity of Triton Valor EMS to Tokyo Stock Exchange’s CONNEQTOR
September 10, 2024 07:00 ET
|
Virtu Financial, LLC
NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Virtu Financial, Inc. (NASDAQ: VIRT), a leading provider of global, multi-asset financial services that delivers liquidity and innovative, transparent...
Mural Oncology to Host First Virtual Investor Day on September 26, 2024
September 10, 2024 07:00 ET
|
Mural Oncology, Inc.
Company will provide clinical overview and update on late-stage clinical candidate, nemvaleukin alfa, and overview of IL-18 pipeline program Clinicians to share expert perspectives around the...
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
September 10, 2024 07:00 ET
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference